http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107050028-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107050028-B |
| titleOfInvention | Purposes of pyridine derivatives (the E)-MSTC in preparation treatment ovarian cancer |
| abstract | The invention discloses a kind of application of pyridine derivatives in preparation treatment ovarian cancer, belong to technical field of pharmaceutical biotechnology；The compound is (E) -4- styryl-5,6,7,8- tetrahydroquinoline -2- carboxylate methyl ester, referred to as (E)-MSTC), compound (the E)-MSTC that the present invention is filtered out has specific inhibitory effect to ovarian cancer cell, but without influence or influences very little to normal human desmocyte IMR90 cell；Cell cycle detection proves that it has certain retardation to the cell cycle of ovarian cancer cell, and Apoptosis detection proves that the compound can also promote the apoptosis of ovarian cancer cell；To judge that it has remarkable effect in terms of specific ovarian cancer resistance；This compound can become the lead compound for the treatment of oophoroma, have good prospect for the exploitation of further ovarian cancer resistance medicament. |
| priorityDate | 2016-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.